Showing results 1 to 1 of 1
| Title | Author(s) | Issue Date | |
|---|---|---|---|
First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN Proceeding/Conference:Annals of Oncology | 2021 |
| Title | Author(s) | Issue Date | |
|---|---|---|---|
First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN Proceeding/Conference:Annals of Oncology | 2021 |